| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Gene Therapies | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Gene Therapies | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Gene Therapies | Oncology |
Recent Updates
Recently added Catalysts
Arvinas, Inc.$8.27
-0.27 (-3.16%)
D 34Pipeline Score Overvalued Biotech · Commercial
Market Cap
516.17 M
EPS
-3.26
P/E Ratio
-2.46 $
Value Trade
9.83 M
SEC Financials
Q1 2026Dilution Risk
Revenue
15.60 M
R&D Expenses
60.30 M
Operating CF
-69.20 M
Total Assets
647.50 M
Total Liabilities
260.70 M
Equity
386.80 M
D/E Ratio
12,345
-2.26 %
Week
-15.05 %
1 Month
-26.22 %
3 Month
-17.36 %
6 Month
-86.43 %
5 Year
-56.71 %
All Time
Cash Data
Cash Position
614.90 M
Monthly Burn
23.07 M
Runway
24.7 mo
Burn Trend
StableSEC Filing
May 11, 2026
Overview
Volume
423.18 K
52 Week Range
6.06 - 14.51
% held by Insiders
13.41 %
% held by Institutions
76.08 %
Enterprise Value
-90.13 M
Total Shares
64.50 M
Short %
8.21 %
Float Shares
51.98 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Arvinas, Inc.
509Total events
7Upcoming
104Tier-1 (high impact)
2018 – 2026Coverage
Upcoming catalysts 7
Event history 502
Jun 5, 2026
▲PDUFA DateVEPPANUApprovedRegulatory Filing
PDUFA date of June 5, 2026 (approval received ahead of this date)
ER+/HER2- ESR1-mutated advanced or metastatic breast cancersource ↗
Jun 5, 2026
◆PDUFA DatevepdegestrantRegulatory Filing
PDUFA action date for vepdegestrant monotherapy
ER+/HER2- advanced or metastatic breast cancer with ESR1 mutationssource ↗
Jun 4, 2026
▲Partnership / LicenseARV-102Corporate
Joined LITE and PPMI programs supported by MJFF
Parkinson's diseasesource ↗
Jun 3, 2026
◆Oral PresentationPresentation
Management to participate in fireside chat at Jefferies Global Healthcare Conference
May 12, 2026
▲Partnership / LicenseVEPPANUApprovedCorporate
License agreement with Rigel for exclusive global rights to VEPPANU
ER+/HER2- ESR1-mutated advanced or metastatic breast cancersource ↗
May 12, 2026
▲FDA ApprovalVEPPANUApprovedFDA Decision
FDA approval of VEPPANU (vepdegestrant)
ER+/HER2- ESR1-mutated advanced or metastatic breast cancersource ↗
May 12, 2026
▲Oral PresentationARV-102Presentation
Presented Phase 1 data for ARV-102 at AD/PD 2026
Parkinson's diseasesource ↗
May 12, 2026
▲Poster PresentationARV-6723Presentation
Presented preclinical data at AACR Immuno-Oncology Conference
Solid tumorssource ↗
May 12, 2026
▲First Patient DosedARV-027Trial
Initiated dosing with ARV-027 in Phase 1 healthy volunteer trial
Healthy volunteerssource ↗
May 12, 2026
▲Enrollment CompleteARV-806Trial
Completed dose escalation enrollment in Phase 1 trial of ARV-806
Solid tumors with KRAS G12D mutationssource ↗
Drug Pipeline Intelligence
D34
Pipeline Score $102M
Pipeline ValueOvervalued
Valuation Signal5
Drugs Scored0.2x
rNPV / MCap Top 46%
Micro Cap (rank 493 of 912)
Percentile RankArvinas, Inc. faces pipeline headwinds (34/100), with $255M risk-adjusted pipeline value, led by ARV-471 in Breast Cancer (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARV-471 Small molecule | Breast Cancer | Phase 2 | NCT04072952 | 10% | $80M | COMPLETED | 369 | FAST | C (47) | Mar 5, 2026 | MODERATE_RISK | MEDIUM May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ARV-102 | Parkinson's disease | Phase 1 | 2026-03-18 | greater than 50% LRRK2 degradation in the CSF; approximately 50% or greater reduction of LRRK2 in cerebrospinal fluid (CSF) at all doses by day 14; maintained the reduction through day 28 Read More | Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days Read More | |
ARV-102 | Parkinson's disease | Phase 1 | 2026-03-18 | greater than 50% LRRK2 degradation in the CSF; approximately 50% or greater reduction of LRRK2 in cerebrospinal fluid (CSF) at all doses by day 14; maintained the reduction through day 28 Read More | Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days Read More | |
ARV-102 | Parkinson's disease | Phase 1 | 2026-03-18 | greater than 50% LRRK2 degradation in the CSF; approximately 50% or greater reduction of LRRK2 in cerebrospinal fluid (CSF) at all doses by day 14; maintained the reduction through day 28 Read More | Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ARVN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ARVN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ARVNArvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
Arvinas, Inc. has joined the LRRK2 Investigative Therapeutics Exchange (LITE) and the Parkinson’s Precision Medicine Initiative (PPMI), programs supported by The Michael J. Fox Foundation. This collaboration aims to advance ARV-102, Arvinas’ investigational treatment targeting LRRK2 for conditions like Parkinson's disease. The initiatives will focus on enhancing understanding of LRRK2 biology and accelerating the development of targeted therapies. Arvinas has a commitment to improving treatments for neurodegenerative diseases through innovative research.
Read more →ARVN▼ -6.8%on this newsshared move
presentationj
presentationj
Read more →ARVNArvinas to Present at Jefferies Global Healthcare Conference 2026
Arvinas, Inc. will present at the Jefferies Global Healthcare Conference on June 3, 2026. The company is known for its innovative drug development using targeted protein degradation. They have successfully developed the first FDA-approved PROTAC for treating advanced breast cancer and are advancing multiple investigational drugs for various diseases.
Read more →ARVNArvinas to Present at Jefferies Global Healthcare Conference
Arvinas, Inc. will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026. The company is known for its innovative protein degradation therapies and has developed the first FDA-approved PROTAC for treating advanced breast cancer. Arvinas is also advancing several investigational drugs targeting various diseases.
Read more →ARVNArvinas Employees Give Back During Company-wide Impact Day
Arvinas, a clinical-stage biotechnology company, celebrated its fourth Company-wide Impact Day, where employees engaged in various community service activities across multiple locations. The company emphasizes its commitment to both patients and the communities where it operates. This year's initiatives included preparing meals for patients, creating comforting blankets, and beautifying local spaces. The event demonstrates Arvinas' dedication to making a positive impact. CEO Randy Teel expressed pride in the employees' passion for community service.
Read more →ARVNArvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
Arvinas, Inc. reported its first quarter 2026 financial results and corporate updates, highlighting significant developments including the FDA approval of VEPPANU, a groundbreaking PROTAC for advanced breast cancer. The approval marks a milestone as it is the first of its kind, correlating with Arvinas' long-term focus on targeted protein degradation. Additionally, Phase 1 clinical trials show encouraging results for other drug candidates like ARV-102 for Parkinson's disease. Arvinas is also expanding collaborations and planning further trials, reinforcing its growth trajectory in the biotechnology sector.
Read more →ARVNArvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
Arvinas and Pfizer have entered into a license agreement with Rigel Pharmaceuticals for the exclusive global rights to VEPPANU (vepdegestrant), an FDA-approved PROTAC therapy for certain types of breast cancer. The agreement includes an initial payment of $85 million, with opportunities for additional payments based on development milestones. Rigel will handle commercialization in the U.S., while Arvinas and Pfizer will continue their development efforts. The transaction is subject to necessary regulatory approvals, which could delay the implementation of their plans.
Read more →ARVNArvinas to Report First Quarter 2026 Financial Results on May 12, 2026
Arvinas, Inc. will report its first quarter 2026 financial results and provide a corporate update on May 12, 2026. The live webcast will begin at 8:00 a.m. ET and will be accessible on the company's investor page. Arvinas is known for its innovative protein degradation therapies and has made significant advancements in treating various cancers and neurodegenerative disorders.
Read more →ARVN▲ +6.2%on this newsshared move
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
Arvinas, in partnership with Pfizer, has received FDA approval for VEPPANU (vepdegestrant), marking the first-ever approval of a PROTAC therapy. This drug targets advanced breast cancer in adults with ESR1 mutations, offering a new treatment option for patients who have progressed after initial endocrine therapy. The approval was granted ahead of the scheduled PDUFA date of June 5, 2026, reflecting a significant milestone in the field of oncology. Preliminary clinical trial results indicated improved progression-free survival compared to standard therapies, although some risks associated with treatment remain.
Read more →ARVN▼ -9.3%on this news
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days
Arvinas has presented positive Phase 1 clinical trial data for ARV-102, an investigational drug targeting LRRK2 in Parkinson's disease patients. The trial demonstrated a reduction of LRRK2 levels in cerebrospinal fluid by over 50% after 28 days of once-daily dosing. ARV-102 was well tolerated with no serious adverse events reported, supporting its potential for further development in neurodegenerative diseases linked to LRRK2 dysfunction. The data were highlighted during an oral session at the AD/PD™ 2026 conference.
Read more →ARVNArvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
Arvinas, Inc. will present Phase 1 clinical trial data for ARV-102 at the 2026 International Conference on Alzheimer's and Parkinson's Diseases. The investigational drug aims to target and degrade LRRK2, a protein implicated in Parkinson’s disease. The company plans to initiate a Phase 1b trial for ARV-102 in progressive supranuclear palsy pending regulatory feedback. The presentation will take place on March 18, 2026, focusing on safety, pharmacokinetics, and pharmacodynamics related to the treatment.
Read more →ARVNArvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Arvinas, Inc. reported its fourth quarter and full year 2025 financial results, highlighting significant advancements in its clinical pipeline, including upcoming data readouts for several investigational drugs. The company has sufficient cash to support operations into 2028, despite a decrease in cash reserves and revenue from collaboration agreements. CEO Randy Teel emphasized the company's strategic focus on addressing unmet medical needs in oncology and neurology.
Read more →ARVNArvinas to Participate in Upcoming Investor Conferences
Arvinas, Inc. has announced its participation in four upcoming investor conferences, highlighting its commitment to engaging with investors. The company is focused on developing targeted protein degradation therapies through its PROTAC platform. Arvinas is advancing multiple investigational drugs aimed at various serious conditions, including neurodegenerative disorders and cancers.
Read more →ARVNArvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Arvinas, Inc. will report its fourth quarter and full year 2025 financial results on February 24, 2026. The management will provide a corporate update during a live webcast at 8:00 a.m. ET. The webcast will be accessible on the Arvinas investor page, with a replay available afterward.
Read more →ARVN▼ -9.6%on this newsshared move
Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director
Arvinas, Inc. has appointed Randy Teel, Ph.D., as its new President and CEO, succeeding John Houston, Ph.D., who will remain on the Board. Teel, previously the Chief Business Officer, is recognized for his strategic leadership and experience in advancing the company's growth. Under his leadership, Arvinas aims to build on its successful clinical pipeline and continue its momentum in the biotechnology sector.
Read more →ARVNArvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition
Arvinas, Inc. presented promising preclinical data at the 67th ASH Annual Meeting, demonstrating that the combination of ARV-393 and glofitamab significantly enhances tumor growth inhibition in a model of diffuse large B-cell lymphoma. The company plans to initiate a Phase 1 clinical trial for this combination in 2026, aiming to provide a chemotherapy-free treatment alternative for patients. This development underscores the potential of ARV-393 in addressing unmet medical needs in aggressive lymphoma cases.
Read more →ARVNArvinas to Present at Piper Sandler 37th Annual Healthcare Conference
Arvinas, Inc. announced that its Chief Medical Officer and Chief Financial Officer will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4. The event will be accessible via a live audio webcast. Arvinas is focused on developing innovative therapies using its PROTAC platform to target disease-causing proteins.
Read more →ARVNArvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)
Arvinas, Inc. announced that several abstracts on vepdegestrant (ARV-471) will be presented at the 2025 San Antonio Breast Cancer Symposium. Vepdegestrant is being developed as a treatment for ER+/HER2- advanced breast cancer. The FDA is reviewing its New Drug Application, with a PDUFA action date set for June 5, 2026.
Read more →ARVNArvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Arvinas reported its third quarter 2025 financial results, highlighting progress in its clinical pipeline, including positive Phase 1 data for ARV-102 in Parkinson's disease. The company also presented promising preclinical data for ARV-806 and ARV-027. A collaboration with Pfizer for vepdegestrant was announced, and financial guidance suggests sufficient resources to support operations through 2028.
Read more →ARVNArvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting
Arvinas, Inc. announced that it will present preclinical data for its investigational drug ARV-393 at the 2025 ASH Annual Meeting. ARV-393 is designed to degrade the BCL6 protein, which is significant in B-cell lymphomas. The presentation will highlight its potential in combination with glofitamab, a bispecific antibody. The company continues to advance its clinical programs.
Read more →ARVNArvinas to Report Third Quarter 2025 Financial Results on November 5, 2025
Arvinas, Inc. will report its third quarter 2025 financial results on November 5, 2025. The management will provide a corporate update during a live webcast at 8:00 a.m. ET. The company is advancing several investigational drugs targeting various diseases through its innovative protein degradation platform.
Read more →ARVNArvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Arvinas presented promising preclinical data for ARV-806, a PROTAC KRAS G12D degrader, at the 2025 AACR-NCI-EORTC conference. The data indicate significant tumor growth inhibition in pancreatic, colorectal, and lung cancer models. ARV-806 targets both ON and OFF forms of KRAS G12D, suggesting its potential to address unmet needs in treating these cancers.
Read more →ARVNArvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Arvinas, Inc. announced that it will present preclinical data for ARV-806, a PROTAC KRAS G12D degrader, at the 2025 AACR-NCI-EORTC Conference in Boston. The drug targets the KRAS G12D mutation, prevalent in various solid tumors, and is currently undergoing Phase 1 clinical trials. This presentation highlights the company's commitment to addressing significant unmet needs in cancer treatment.
Read more →ARVNPatient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy
Arvinas, Inc. announced positive patient-reported outcomes from the Phase 3 VERITAC-2 clinical trial for vepdegestrant, a novel treatment for ESR1-mutated ER+/HER2- advanced breast cancer. The data presented at the ESMO Congress showed significant improvements in quality of life and reduced pain compared to fulvestrant. This reinforces vepdegestrant's potential as a leading therapy in this patient population.
Read more →ARVNArvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress
Arvinas, Inc. announced that new data on vepdegestrant will be presented at the ESMO Congress in October 2025. This investigational drug is being developed for treating advanced breast cancer with specific mutations. The presentation will include patient-reported outcomes from the Phase 3 VERITAC-2 trial, showcasing the drug's potential effectiveness. Ongoing studies are also assessing its use in combination therapies.
Read more →ARVNArvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
Arvinas, Inc. presented positive Phase 1 clinical data for ARV-102, a PROTAC LRRK2 degrader, at the MDS 2025 Congress. The trials showed that ARV-102 was well tolerated and resulted in dose-dependent cerebrospinal fluid exposure. Notably, after 14 days of treatment, the drug decreased biomarkers linked to Parkinson's disease. The company plans to advance ARV-102 into further studies for Parkinson's and progressive supranuclear palsy.
Read more →ARVN▲ +7.2%on this newsshared move
Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
Arvinas, Inc. is set to present clinical data for its investigational drug ARV-102 at the 2025 International Congress of Parkinson’s Disease and Movement Disorders. Two presentations will include findings from a first-in-human study assessing the drug's safety and pharmacodynamics, aimed at treating neurodegenerative conditions linked to LRRK2 mutation. The company's innovative PROTAC technology focuses on targeted protein degradation, potentially offering breakthroughs in treatment for diseases such as Parkinson's.
Read more →ARVNArvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation
Arvinas Inc. has announced a strategic update regarding its collaboration with Pfizer on the investigational drug vepdegestrant. The companies plan to out-license commercialization rights, seeking a third-party partner to maximize its market potential. Arvinas has initiated cost optimization measures expected to save over $100 million annually, which includes reducing its workforce by 15%. The company has also authorized a stock repurchase program of up to $100 million, reaffirming its cash runway through the second half of 2028.
Read more →ARVNArvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
Arvinas, in partnership with Pfizer, has received FDA acceptance for its New Drug Application for vepdegestrant, targeting ER+/HER2- advanced breast cancer. This decision follows positive results from the VERITAC-2 clinical trial, which showed vepdegestrant can improve progression-free survival compared to fulvestrant. The FDA has set a PDUFA action date of June 5, 2026, and granted the drug Fast Track designation due to unmet medical needs. If approved, vepdegestrant is expected to be a leading treatment option for affected patients who have limited alternatives after first-line therapy.
Read more →ARVN▼ -15.5%on this newsshared move
Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+ HER2- advanced or metastatic breast cancer - - Presen
Arvinas reported notable progress in Q2 2025, including the submission of a New Drug Application for vepdegestrant, a first for PROTAC degraders. During the quarter, the company also presented promising data for its ARV-102 and ARV-393 programs, alongside initiating a trial for ARV-806. Although the clinical trial for vepdegestrant showed a median progression-free survival improvement, it failed to achieve statistical significance for the overall treated cohort. The company continues to advance its pipeline with a number of upcoming milestones anticipated in the next year.
Read more →ARVNArvinas to Report Second Quarter 2025 Financial Results on August 6, 2025
Arvinas, Inc. announced that it will report its second quarter 2025 financial results on August 6, 2025, during a live webcast. The company, focused on creating targeted protein degradation therapies, is advancing several investigational drugs in clinical development, which may have significant implications for patients with various diseases. This webcast will be an opportunity for stakeholders to gain insights into the company’s financial performance and corporate initiatives.
Read more →ARVNArvinas Announces Retirement of Chief Executive Officer and Succession Plan
John Houston, Ph.D., is set to retire from his role as CEO of Arvinas following the appointment of a successor, while still serving as Chairperson of the Board. The Arvinas Board is initiating a search for a new CEO, emphasizing a commitment to a seamless transition. During his tenure, Dr. Houston has led significant milestones in developing targeted protein degradation therapies. Arvinas remains focused on advancing its PROTAC platform to improve patient outcomes across several therapeutic areas.
Read more →ARVNArvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress
Arvinas, Inc. presented promising preclinical data for its investigational drug ARV-393 at the European Hematology Association 2025 Congress. The drug exhibited significant activity as a single agent in models of various B-cell lymphomas and showed improved tumor regression when combined with small molecule inhibitors. These findings suggest potential utility for ARV-393 in treating a spectrum of non-Hodgkin lymphoma, including forms with unmet medical needs. A Phase 1 clinical trial is currently enrolling patients with relapsed/refractory lymphoma.
Read more →ARVN▲ +8.8%on this news
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
Arvinas, Inc. has announced the submission of a New Drug Application to the FDA for vepdegestrant, aimed at treating patients with advanced or metastatic breast cancer with specific ESR1 mutations. This submission follows promising results from the Phase 3 VERITAC-2 trial, which showcased vepdegestrant's efficacy as compared to fulvestrant. The drug has also received Fast Track designation from the FDA, emphasizing its potential importance for patients in need of new treatment options in this category.
Read more →ARVN▲ +8.8%on this news
developed as a potential monotherapy for ER+/HER2- advanced or metastatic breast cancer with estrogen receptor 1 (ESR1) mutations in the second line-plus setting. In July 2021, Arvinas announced a global collaboration wi
Arvinas has announced the submission of a New Drug Application (NDA) to the FDA for vepdegestrant, aimed at treating ER+/HER2- advanced or metastatic breast cancer with ESR1 mutations. This decision follows positive results from the Phase 3 VERITAC-2 clinical trial, which demonstrated the drug's potential compared to fulvestrant. Notably, vepdegestrant has received fast track designation, highlighting its importance for patients in this treatment area. The approval process could take uncertain timeframes, and clinical outcomes remain to be fully assessed.
Read more →ARVNArvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting
Arvinas, Inc. has announced it will present preclinical data for ARV-393, an investigational PROTAC BCL6 degrader, at the European Hematology Association Annual Meeting in Milan, Italy, from June 12-15, 2025. This compound aims to effectively target BCL6, a key protein involved in various B-cell lymphomas. The presentation will include results from studies demonstrating the preclinical efficacy of ARV-393 in lymphoma models, showcasing its potential as a treatment option for patients. The company continues to pursue clinical trials for ARV-393, which is currently in Phase 1 evaluation for relapsed/refractory non-Hodgkin lymphoma.
Read more →ARVNArvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
Arvinas, Inc. and Pfizer presented results from the Phase 3 VERITAC-2 trial showcasing that vepdegestrant significantly improves progression-free survival in patients with ESR1-mutant advanced breast cancer. The drug showed a median PFS of 5.0 months compared to 2.1 months for fulvestrant, demonstrating a 43% reduction in the risk of disease progression. Though the treatment was well tolerated, overall survival data remains immature. The companies plan to file a New Drug Application for vepdegestrant in the second half of 2025.
Read more →ARVNARVINAS ALERT: Bragar Eagel & Squire, P.C. is Investigating Arvinas, Inc. on Behalf of Arvinas Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Arvinas, Inc. on behalf of stockholders due to potential violations of federal securities laws. This follows Arvinas's recent decision to discontinue the development of vepdegestrant, an oral SERD for HR-positive breast cancer, resulting in a sharp decline in its share price. The sudden announcement, which included the halt of two planned Phase 3 studies, raised questions from analysts about the company's communication with investors. Stockholders affected by this situation are encouraged to reach out to the law firm for assistance.
Read more →ARVN▼ -24.8%on this news
Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update - Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings - - Presented first-in-human
Arvinas, Inc. reported its first quarter 2025 financial results and announced promising results from its Phase 3 VERITAC-2 trial, which support their global regulatory filings. The company also presented first-in-human data for ARV-102, highlighting its ability to penetrate the blood-brain barrier. However, Arvinas has initiated workforce reductions and removed two Phase 3 trials from its development plan to extend its cash runway into 2028. The company's CEO expressed confidence in their therapy's potential for treating metastatic breast cancer alongside a strategic shift in their research portfolio.
Read more →ARVNArvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting
Arvinas, Inc. presented promising preclinical data for ARV-393, a PROTAC BCL6 degrader, at the 2025 AACR annual meeting. The results showed that ARV-393 in combination with standard chemotherapy and biologics led to complete tumor regressions in aggressive lymphoma models. The findings underscore the potential of ARV-393 for broad combinability in treating non-Hodgkin lymphoma, encouraging further exploration in clinical settings. A Phase 1 study of ARV-393 in relapsed/refractory non-Hodgkin lymphoma is currently ongoing.
Read more →ARVNArvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
Arvinas, Inc., a clinical-stage biotechnology company, announced that it will report its first quarter 2025 financial results during a live webcast on May 1, 2025. The presentation will provide insights into the company's performance and an update on its drug development pipeline. Arvinas is focused on developing targeted protein degradation therapies and has several investigational drugs in progress for various cancers and neurodegenerative disorders. Interested parties can access the webcast and subsequent replay on the company's investor page.
Read more →ARVNArvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Arvinas, Inc. announced that results from its Phase 3 VERITAC-2 trial will be presented as a late-breaking oral presentation at the 2025 ASCO Annual Meeting. The trial evaluates vepdegestrant versus fulvestrant in treating ER+/HER2- advanced breast cancer. This marks the first detailed presentation of pivotal data for vepdegestrant, an investigational oral PROTAC estrogen receptor degrader. The drug is being co-developed with Pfizer and has received Fast Track designation from the FDA.
Read more →ARVNArvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research (AACR) Annual Meeting
Arvinas, Inc. has announced the upcoming presentation of preclinical data for its investigational drug ARV-393 at the 2025 AACR Annual Meeting. ARV-393, a PROTAC degrader targeting the BCL6 protein, has shown promise in preclinical trials for combination with established lymphoma treatments. This presentation underscores the potential of ARV-393 to effectively treat relapsed or refractory non-Hodgkin lymphoma and highlights advances in the company's drug development pipeline. The poster session is scheduled for April 28, 2025, in Chicago, Illinois.
Read more →ARVNArvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation
Arvinas, Inc. has presented positive data from its first-in-human trial of ARV-102, a novel investigational oral PROTAC targeting LRRK2, indicating its effectiveness in reducing LRRK2 levels in both central and peripheral sites. The study showed that ARV-102 was well tolerated by participants, with substantial brain penetration and no serious adverse events reported. Given these results, Arvinas is moving forward with further evaluations of ARV-102 in patients with Parkinson’s disease. The data was well-received at the 2025 International Conference on Alzheimer's and Parkinson's Diseases in Vienna, Austria.
Read more →ARVNArvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases
Arvinas, Inc. has announced that it will present data from the first-in-human study of its investigational drug ARV-102 at the upcoming International Conference on Alzheimer's and Parkinson's Diseases in April 2025. The study focuses on the safety, pharmacokinetics, and pharmacodynamics of ARV-102, which is designed to target LRRK2, a protein linked to neurological diseases such as Parkinson’s and progressive supranuclear palsy. This presentation marks a significant step for Arvinas in its commitment to developing innovative therapies based on targeted protein degradation.
Read more →ARVN▼ -52.7%on this news
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
Arvinas, Inc. and Pfizer Inc. reported positive topline results from the Phase 3 VERITAC-2 clinical trial, where vepdegestrant demonstrated significant improvements in progression-free survival in patients with estrogen receptor-positive metastatic breast cancer. While the primary endpoint was met in the ESR1-mutant population, results did not include significant improvements for the overall patient population. Further data regarding overall survival will continue to be analyzed as the trial progresses and vepdegestrant shows promise as a potential treatment option. The findings are set to be presented at a medical conference in 2025.
Read more →ARVN▼ -52.7%on this news
Arvinas Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve su
Arvinas and Pfizer are advancing vepdegestrant, a novel ER degrader for ER+/HER2- metastatic breast cancer, evidenced by safety data presented from the Phase 3 VERITAC-2 clinical trial. While the critical overall survival metrics remain immature, the safety profile appears consistent with prior studies. The FDA has granted Fast Track designation for vepdegestrant, and further detailed results are anticipated to be discussed with regulatory authorities. Despite potential benefits, challenges persist in securing clinical success and regulatory approval.
Read more →ARVN▼ -6.8%on this news
Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial is anticipated in 1Q25 - - Presented Phase 1b d
Arvinas has reported its financial results for the fourth quarter and full year 2024, alongside a corporate update detailing significant pipeline progress. The company expects to release topline data from its Phase 3 VERITAC-2 trial in ER+ HER2- metastatic breast cancer by 1Q25 and has presented promising Phase 1b data from the TACTIVE-U study. Several new Phase 3 combination trials are planned for 2025, while cash and cash equivalents have decreased, indicating a need for careful financial management as the company invests heavily in its research and development efforts.
Read more →ARVNArvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
Arvinas, Inc. announced it will host a webcast on February 11, 2025, to discuss its fourth quarter and full year 2024 financial results, alongside a corporate update. The biotechnology company specializes in targeted protein degradation and is developing several investigational drugs for various conditions, including breast cancer and neurodegenerative disorders. Participants can access the live event through the investor page on Arvinas' website, where a replay will also be available afterward.
Read more →ARVN▼ -6.1%on this news
Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update
Arvinas, Inc. has announced updates regarding its clinical trials for vepdegestrant, an investigational drug for treating ER+/HER2- metastatic breast cancer. The company plans to initiate first- and second-line Phase 3 trials in 2025, with topline data from the monotherapy Phase 3 VERITAC-2 trial expected in early 2025. Additionally, Arvinas has started a Phase 1 trial for its ARV-102 drug targeting Parkinson's disease and will disclose progress on various trials, including ARV-393 for B-cell lymphomas. The company has also appointed Alex Santini as interim Chief Commercial Officer, following the departure of John Northcott.
Read more →ARVNArvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium - Vepdegestrant in combination with abemaciclib
Arvinas and Pfizer presented preliminary Phase 1b data for vepdegestrant combined with abemaciclib at the San Antonio Breast Cancer Symposium. Key findings indicated that the combination therapy had a clinical benefit rate of 62.5% and no significant adverse events, with tolerability consistent with previous studies. The ongoing evaluation of this combination includes patients with prior CDK4/6 inhibitor treatments, and both companies continue to monitor its effectiveness and safety across multiple studies.
Read more →ARVN▲ +6.1%on this news
Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference
Arvinas, Inc. announced that its Chief Medical Officer Noah Berkowitz and Chief Financial Officer Andrew Saik will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024. This event will feature discussions about its innovative approach of using protein degradation for developing therapies. Arvinas is currently developing drugs targeting various critical conditions including breast cancer and neurodegenerative diseases. A live audio webcast of the event will be accessible on their website.
Read more →ARVNArvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium
Arvinas, Inc. has announced that three posters detailing clinical data on vepdegestrant will be presented at the 2024 San Antonio Breast Cancer Symposium from December 10-13. Vepdegestrant is an investigational PROTAC estrogen receptor degrader aimed at treating ER+/HER2- breast cancer, developed in collaboration with Pfizer. The posters will cover various aspects of the drug's efficacy in combination therapies and potential interactions with other drugs. The FDA has granted vepdegestrant Fast Track designation, underscoring its significance in addressing breast cancer treatment challenges.
Read more →ARVNArvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update - On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 - - Initial clinical data from Phase 1 2 TACTIVE-U sub-stu
Arvinas has reported its financial results for Q3 2024, highlighting a solid cash position of $1.1 billion and ongoing progress across its clinical pipeline. The company remains on schedule to release topline data from the Phase 3 VERITAC-2 trial by Q4 2024 or Q1 2025, presenting an optimistic outlook for its ER+ HER2- breast cancer treatment. Additionally, new preclinical data for ARV-102 and updates on other clinical trials enhance the company's position within the biotechnology sector.
Read more →ARVNArvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day
Arvinas, Inc. held its third annual 'Impact Day,' a company-wide service initiative where employees from 16 states volunteered in various community projects. Activities included environmental cleaning efforts along the Long Island Sound and beautifying local Boys and Girls Club locations. The CEO praised the dedication of employees in supporting vital community organizations. This initiative reflects Arvinas' commitment to corporate social responsibility and making a positive impact in the Greater New Haven area.
Read more →ARVNArvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024
Arvinas, Inc. announced that it will host a live webcast on October 30, 2024, to discuss its third quarter financial results and provide a corporate update. The company, which specializes in targeted protein degradation therapies, aims to improve treatments for patients with serious diseases. The event will be accessible to investors via the Arvinas website, further demonstrating the company's commitment to transparency and stakeholder engagement.
Read more →ARVNArvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update - Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting continued enrollment globally in m
Arvinas, Inc. reported its financial results for Q2 2024, highlighting significant progress in clinical trials, including the completion of enrollment for the VERITAC-3 Phase 3 trial. The company received $150 million following a strategic licensing agreement with Novartis, with the potential for additional contingent payments. Leadership changes were announced to enhance operational capabilities. Key upcoming milestones include topline data expectations from the VERITAC-2 trial by late 2024 or early 2025.
Read more →ARVNArvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
Arvinas, Inc. has appointed Andrew Saik as its new Chief Financial Officer and Treasurer, effective June 24, 2024. Saik, who has over 20 years of biopharma finance experience, will report to CEO John Houston and is expected to contribute significantly to Arvinas' financial strategy as the company transitions to a commercial-stage biotech. The appointment comes as Arvinas progresses through multiple clinical-stage programs, positioning itself for upcoming Phase 3 data readouts. Saik's previous experience at Intercept Pharmaceuticals and other firms highlights his capability in financial management within the biopharmaceutical industry.
Read more →ARVNArvinas Announces Presentations for Two of its PROTAC Investigational Programs Targeting BCL6 and LRRK2
Arvinas, Inc. has presented promising preclinical data for its investigational programs targeting BCL6 and LRRK2 at recent international congresses. ARV-393 demonstrated effective anti-tumor activity in models of B-cell lymphoma and is currently in a phase 1 clinical trial for non-Hodgkin lymphoma. Additionally, data on PROTAC LRRK2 degraders highlighted their potential to treat neurodegenerative diseases with a favorable safety profile, potentially addressing the challenges of traditional therapies. Both programs aim to leverage protein degradation technology for targeted treatments.
Read more →ARVNArvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
Arvinas, Inc. has promoted Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer. These promotions are expected to bolster the company's leadership as it continues to innovate in the field of targeted protein degradation. Both Taylor and Cacace have made significant contributions to Arvinas, with Taylor having been pivotal in advancing its research and development endeavors and Cacace integral in developing the company's neuroscience capabilities. Their new roles come at a crucial time as Arvinas aims to push its clinical pipeline forward.
Read more →ARVNArvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
Arvinas, Inc. has announced that two of its abstracts have been accepted for presentation at the 2024 American Society of Clinical Oncology Annual Congress. These abstracts focus on ARV-766, a drug targeting prostate cancer, and TACTIVE-K, a study on a novel ER degrader in combination with a CDK4 inhibitor for breast cancer. The presentations are scheduled for early June 2024, coinciding with a commitment to advancing its investigational therapies through partnerships, including a recent agreement with Novartis. Both drugs are part of Arvinas's innovative approach to protein degradation in cancer treatment.
Read more →ARVNArvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE )
Arvinas and Pfizer have shared promising updated clinical data for vepdegestrant, evaluated in a Phase 1b trial alongside palbociclib for ER+/HER2- breast cancer. The study indicated a 63% clinical benefit rate, with a median progression-free survival of 13.9 months at the recommended dose. Circulating tumor DNA analyses showed significant reductions in tumor fractions regardless of ESR1 gene mutation status. Although the combination displayed a good safety profile, instances of Grade 3/4 adverse events, including neutropenia, were noted.
Read more →ARVNArvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
Arvinas, Inc. has announced that it will present two posters featuring updated clinical trial data for vepdegestrant at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany, from May 15-17, 2024. Vepdegestrant is a novel PROTAC estrogen receptor degrader jointly developed with Pfizer for the treatment of ER+/HER2- breast cancer. The posters will showcase results from two clinical trials and highlight the drug's potential as both a monotherapy and in combination treatments. This development comes alongside the FDA granting Fast Track designation for vepdegestrant in relevant cancer cases.
Read more →ARVN▲ +6.4%on this newsshared move
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update - Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+ HER2- metastatic breast cancer, including the VERITA
Arvinas recently reported its financial results for the first quarter of 2024, highlighting ongoing global enrollment in clinical studies for vepdegestrant in ER+ HER2- metastatic breast cancer. A notable transaction with Novartis will provide an upfront payment of $150 million and significant milestone opportunities. Additionally, Arvinas initiated a Phase 1 clinical trial for ARV-102, aiming to address neurodegenerative diseases. The company maintains a robust financial position, projected to sustain operations through 2027, while remaining on track for key data readouts later this year.
Read more →ARVNArvinas to Present at Upcoming Investor Conferences
Arvinas, a clinical-stage biotechnology company, has announced its participation in two upcoming investor conferences. The company will showcase its progress in targeted protein degradation therapies at the BofA Securities 2024 Healthcare Conference and the UBS Spring Biotech Conferences. Notably, key executives will be involved in discussions that could enhance investor engagement and highlight their innovative research pipeline. With multiple investigational programs in development, Arvinas aims to address significant medical needs in various diseases.
Read more →ARVNArvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
Arvinas, Inc. has appointed Randy Teel, Ph.D., as the Chief Business Officer, a newly established position within the company. Dr. Teel, who has been with Arvinas for nearly six years and currently serves as interim CFO and Treasurer, will continue to report to CEO John Houston. He brings almost 20 years of biopharmaceutical experience and aims to drive business development and corporate strategy. The company is noted for its innovative PROTAC® technology in drug development.
Read more →ARVNArvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
Arvinas has formed an exclusive global license agreement with Novartis for the development and commercialization of its PROTAC androgen receptor degrader, ARV-766, aimed at treating prostate cancer. As part of the deal, Arvinas will receive an upfront payment of $150 million and could earn up to $1.01 billion in additional milestones. Novartis will oversee all worldwide clinical development and commercialization efforts. This partnership is anticipated to enhance the potential of ARV-766 as a leading treatment option for prostate cancer patients.
Read more →ARVN▼ -5%on this news
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Arvinas, Inc. has appointed Noah Berkowitz, M.D., Ph.D., as its new Chief Medical Officer. Berkowitz, who previously held senior positions at Bristol-Myers Squibb, is expected to lead the clinical development of Arvinas’ PROTAC® protein degrader programs, particularly in oncology and neuroscience. His extensive experience over 20 years in clinical trial design and execution is anticipated to drive advancements in Arvinas' pipeline. The company is approaching its first Phase 3 data readout, highlighting the significance of this leadership change.
Read more →ARVNArvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471) in ER+ HER2- metastatic breast can
Arvinas Inc. reported its financial results for Q4 and full year 2023, outlining steady progress in its clinical development of vepdegestrant for ER+ HER2- metastatic breast cancer. The company continues to pursue regulatory discussions for new Phase 3 trials while having initiated several other clinical studies targeting various types of cancer. Despite receiving Fast Track designation for vepdegestrant, challenges remain with the recent resignation of the CFO, raising questions about future financial leadership.
Read more →ARVNArvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC Protein Degrader for Neurodegenerative Disease
Arvinas, Inc. has announced the first human dosing of ARV-102 in a Phase 1 clinical trial aimed at treating neurodegenerative diseases such as Parkinson's disease. The investigational oral PROTAC protein degrader is designed to cross the blood-brain barrier and target LRRK2, which is implicated in these diseases. The trial's primary focus is on evaluating the safety and pharmacokinetics of ARV-102 in healthy volunteers, with potential implications for developing new therapeutic strategies against debilitating neurological conditions. Arvinas remains committed to advancing its innovative drug development initiatives despite inherent uncertainties.
Read more →ARVNArvinas Announces Chief Financial Officer Transition
Arvinas, Inc. has announced the departure of Chief Financial Officer Sean Cassidy, effective February 29, 2024, after over ten years with the company. Randy Teel, Ph.D., will serve as the interim CFO while a search for Cassidy's permanent replacement is conducted. The company maintains a strong financial profile and is advancing multiple investigational programs in clinical trials, though Cassidy's exit introduces an element of leadership transition.
Read more →ARVN▲ +5.9%on this news
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
Arvinas and Pfizer have received FDA Fast Track designation for their investigational drug vepdegestrant (ARV-471) aimed at treating ER+/HER2- metastatic breast cancer. This designation is intended to expedite the development and review of the drug, which is currently being tested in the Phase 3 VERITAC-2 clinical trial. Vepdegestrant is a novel oral PROTAC protein degrader that targets estrogen receptors, demonstrating significant potential in preclinical studies for effectively reducing tumor size. Both companies are committed to addressing the unmet needs of patients in this area through their collaborative development efforts.
Read more →ARVN▲ +10%on this newsshared move
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology firm, has announced its participation in the 6th Annual Guggenheim Biotechnology Conference. Ron Peck, M.D., and Randy Teel, Ph.D., will conduct a fireside chat on February 7, 2024, in New York. The company focuses on targeted protein degradation therapies and has a pipeline that includes programs for breast cancer and prostate cancer treatment.
Read more →ARVNArvinas Appoints Jared Freedberg as General Counsel
Arvinas, Inc. announced the appointment of Jared Freedberg as General Counsel, bringing with him extensive experience from various pharmaceutical companies. His role is anticipated to be vital in guiding Arvinas through potential product commercialization while enhancing the pipeline of PROTAC® protein degraders. Freedberg expressed enthusiasm for the position, highlighting the importance of supporting the company’s mission to improve patient lives through innovative therapies. The announcement also included specifics about stock options and equity awards granted to Freedberg as part of his employment package.
Read more →ARVN▲ +30.8%on this news· ran to +46% by day 3
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
Arvinas, Inc. has announced a conference call and webcast to discuss data on vepdegestrant presented at the 2023 San Antonio Breast Cancer Symposium. The company plans to expand the development program for this investigational protein degrader, targeting ER positive breast cancer. Vepdegestrant has shown significant efficacy in preclinical studies. This update follows a global collaboration with Pfizer for co-development and co-commercialization efforts.
Read more →ARVNArvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE ) and Plans to Expand Vepdegestrant Development Program
Arvinas and Pfizer announced promising interim results from a Phase 1b trial of vepdegestrant combined with palbociclib in treating ER+/HER2- breast cancer. The trial showed a 42% overall response rate and a median progression-free survival of 11.1 months in heavily pre-treated patients. Both companies plan to expand the vepdegestrant development program to explore further combinations with CDK inhibitors, pending regulatory agreements. The results are expected to be presented at the 2023 SABCS, highlighting the potential of this investigational therapy.
Read more →ARVNArvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
Arvinas and Pfizer have announced that updated clinical trial data for vepdegestrant (ARV-471) will be presented at the 2023 San Antonio Breast Cancer Symposium. The data includes findings from the Phase 1b study of vepdegestrant in combination with palbociclib and the Phase 2 monotherapy study results. The symposium is scheduled from December 5-9, 2023, and highlights the companies' ongoing collaboration for vepdegestrant's development against advanced breast cancer. The updated findings are expected to provide significant insights into the drug's efficacy and safety profile.
Read more →ARVN▲ +10.2%on this newsshared move
Arvinas Announces Oversubscribed $350 Million Private Placement
Arvinas, Inc. has announced a successful oversubscribed private placement of $350 million, aimed at funding its ongoing clinical and preclinical developments. The offering will consist of approximately 12.9 million common shares priced at $21.36 each and pre-funded warrants. The placement is expected to close by November 28, 2023, subject to customary conditions. Arvinas plans to utilize the net proceeds from this fundraising to enhance its pipeline and for working capital.
Read more →ARVN▲ +5.1%on this news
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update - Enrollment continues in the 2L Phase 3 VERITAC-2 trial and study lead-in for the VERITAC-3 1L Phase 3 trial with vepdegestrant Top-line
Arvinas, Inc. has reported its financial results for the third quarter of 2023, highlighting progress in its clinical trials and pipeline development. The company is actively enrolling patients in the Phase 3 VERITAC-2 and VERITAC-3 trials for vepdegestrant, with top-line data expected in the second half of 2024. Encouraging data from the bavdegalutamide trial suggest its efficacy in prostate cancer, leading Arvinas to prioritize the ARV-766 trial instead. However, the company noted a substantial decrease in cash reserves, which could affect future operations despite current funding prospects.
Read more →ARVNcastrate-resistant prostate cancer, and we are prioritizing the initiation of a Phase 3 clinical trial in mCRPC with ARV-766." Bavdegalutamide is a once-daily, oral, first-in-class PROTAC AR degrader that degrades wild t
Arvinas, Inc. presented interim results from its Phase 1/2 trial for bavdegalutamide, showing an 11.1 months rPFS in patients with certain AR mutations. Additionally, data for ARV-766 indicates improved tolerability and broader efficacy compared to bavdegalutamide. As a result, the company will prioritize initiating a Phase 3 clinical trial for ARV-766 in metastatic castration-resistant prostate cancer (mCRPC). The decision reflects confidence in ARV-766's potential as a premier treatment option.
Read more →ARVN▼ -6.6%on this newsshared move
Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company, recently held its second annual 'Arvinas Impact Day,' where nearly 200 employees participated in community service activities in the Greater New Haven area. The employees contributed to various initiatives including environmental clean-ups, STEM education kits for foster youth, and meals for those in need. CEO John Houston emphasized the company's commitment to community involvement and making a positive impact. This initiative not only strengthens the local community but also aligns with Arvinas' core values.
Read more →ARVNArvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023
Arvinas, Inc. has announced that it will present updated data from its Phase 1/2 trial of bavdegalutamide at the ESMO Annual Congress 2023 in Madrid. This investigational drug, designed to treat metastatic castration-resistant prostate cancer, is a PROTAC drug that targets androgen receptors. The presentation is scheduled for October 22, 2023, and will detail the drug's effects on patients with AR ligand-binding domain mutations. The event signifies a key opportunity for Arvinas to showcase its advancements in targeted protein degradation therapies.
Read more →ARVNArvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023
Arvinas, Inc. and Pfizer Inc. announced that they will present updated Phase 1/2 data for vepdegestrant (ARV-471) at the upcoming ESMO Annual Congress. This investigational drug, designed for treating patients with locally advanced or metastatic ER+/HER2- breast cancer, has shown substantial preclinical promise. The presentation is set for October 21, 2023, in Madrid, Spain. Both companies share the development costs, commercialization efforts, and profits for this compound.
Read more →ARVNArvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update - Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471), including VERITAC-2 2L Phase 3 trial and study
Arvinas, Inc. reported its financial results for Q2 2023, highlighting significant progress in its clinical studies for vepdegestrant amid strong enrollment figures. The company noted promising interim results from its Phase 1 trial with ARV-766 for advanced prostate cancer. Alongside its financial update, Arvinas outlined upcoming milestones, including further data presentations scheduled for the second half of 2023 and the initiation of new clinical trials. The firm maintains a strong liquidity position, with sufficient funds to support its programs into 2026.
Read more →ARVN▲ +10.3%on this news
Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC ER degrader being developed in ER+/HER2- Breast Cancer
Arvinas, Inc. and Pfizer Inc. have received an Innovation Passport for vepdegestrant, an investigational PROTAC ER degrader designed for ER+/HER2- breast cancer. This designation aims to expedite market access and regulatory assessment in the U.K., with vepdegestrant entering multiple clinical trial phases. The companies are optimistic about the drug's potential benefits, as they work on integrating it into standard treatment protocols. The Innovation Passport allows for facilitated discussions with regulatory bodies regarding future indications.
Read more →ARVNArvinas Announces Changes to its Board of Directors
Arvinas, Inc. has announced changes to its Board of Directors, with Timothy Shannon stepping down as Chairperson after a decade of service. John Houston has been appointed as the new Chairperson and Sunil Agarwal has joined the Board with a strong background in the life sciences industry. The company continues to prioritize its mission of developing innovative therapies based on targeted protein degradation. This transition aims to strengthen Arvinas' leadership as it advances its clinical programs.
Read more →ARVNArvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations
Arvinas Inc. announced interim data from its Phase 1/2 trial of ARV-766, indicating promising efficacy in men with metastatic castration-resistant prostate cancer (mCRPC), particularly those harboring AR L702H mutations. The drug achieved a 42% PSA50 response in patients with AR ligand binding domain (LBD) mutations. Importantly, ARV-766 was well-tolerated in a heavily pre-treated population, with minimal severe side effects reported. The company plans to initiate further clinical trials to explore its potential in earlier treatment lines.
Read more →ARVNArvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
Arvinas, Inc. and Pfizer have announced that they will present updated data on vepdegestrant (ARV-471) at the 2023 ESMO Breast Cancer Annual Congress. This investigational drug is designed to treat patients with early and locally advanced or metastatic ER+/HER2- breast cancer. Four poster presentations will highlight various studies related to vepdegestrant's efficacy and safety. This collaboration reflects a significant investment in innovative cancer therapy development. However, potential regulatory challenges remain as the drug progresses through clinical trials.
Read more →ARVN▲ +7.6%on this newsshared move
Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update -Multiple vepdegestrant (ARV-471) studies enrolling globally, including Phase 1, 2, and 3 studies- - Preliminary data from the Phase 1b c
Arvinas, Inc. reported its financial results for the first quarter of 2023, highlighting progress in its clinical trials, particularly with vepdegestrant (ARV-471). Preliminary data from a Phase 1b combination study with palbociclib indicated a clinical benefit rate of 60.7%. The company, in collaboration with Pfizer, is set to initiate a safety lead-in for a planned Phase 3 trial. Despite progress, there is a noted increase in grade 3-4 neutropenia in some patients and a decline in cash reserves compared to the previous quarter.
Read more →ARVNArvinas to Present at the Bank of America Securities 2023 Healthcare Conference
Arvinas, Inc. announced its participation in the Bank of America Securities 2023 Healthcare Conference on May 9, where key executives will discuss the company's innovations in drug development. The company specializes in targeted protein degradation, with a focus on developing therapies for serious diseases. It has an active clinical pipeline including treatments for metastatic castration-resistant prostate cancer and ER+/HER2- breast cancer. A live audio webcast of the presentation will be available for interested parties.
Read more →ARVN▲ +5.5%on this news
Arvinas to Present at Stifel Targeted Oncology Day
Arvinas, Inc., a clinical-stage biotechnology company, will have its Chief Scientific Officer and Chief Financial Officer participate in a fireside chat at the Stifel Targeted Oncology Day on April 26, 2023. The company's innovative approach focuses on targeted protein degradation to develop therapies for serious diseases. Arvinas has a solid pipeline, including programs for treating metastatic prostate cancer and ER+/HER2- breast cancer. This event aims to showcase the company's ongoing development efforts in the biotechnology sector.
Read more →ARVNArvinas Appoints Kelly Page as Senior Vice President, Global Head of Oncology Strategy and Program Leadership
Arvinas, Inc. has announced the appointment of Kelly Page as Senior Vice President and Global Head of Oncology Strategy and Program Leadership. Page, with over 25 years in the pharmaceutical industry and extensive experience in oncology, is expected to bring valuable insights to the company's executive team. Her prior leadership roles include significant contributions to AstraZeneca, where she led the commercialization of the hematology drug CALQUENCE®. This strategic addition comes as Arvinas progresses with its development of innovative therapies targeting disease-causing proteins.
Read more →ARVNArvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update - Initiated multiple trials with ARV-471, including a 2L+ Phase 3 trial for patients with metastatic breast cancer - - Pre
Arvinas, Inc. reported its financial results for Q4 2022 and provided a corporate update, highlighting significant progress in their ARV-471 drug development. The company has initiated multiple clinical trials, including a Phase 3 trial for metastatic breast cancer and gained alignment with the FDA for these trials. Despite experiencing a decrease in cash reserves and increased R&D expenses, Arvinas aims to initiate further trials and expects important milestones in 2023 that could lead to the commercialization of its products.
Read more →ARVN▲ +7.2%on this news
Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology firm, will present an overview at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023. CEO John Houston will lead the presentation in San Francisco, which will also be accessible via a live audio webcast. Arvinas specializes in targeted protein degradation therapies, with ongoing programs for treating metastatic prostate and advanced breast cancers.
Read more →ARVN▼ -5.5%on this news
Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)
ARV-471 continues to show activity in heavily pre-treated patients with locally advanced or metastatic ER+/HER2- breast cancer Median progression free survival of 3.7 months in all patients and 5.7 months in patients with ESR1 mutant tumors support the initiation of two Phase 3
Read more →ARVNArvinas Reports Third Quarter 2022 Financial Results and Provides Corporate Update - On track to initiate enrollment of two Phase 3 trials with ARV-471 in patients with first- and second-line metastatic breast cancer - -
Arvinas Reports Third Quarter 2022 Financial Results and Provides Corporate Update - On track to initiate enrollment of two Phase 3 trials with ARV-471 in patients with first- and second-line metastatic breast cancer - - Enrolling multiple clinical trials and initiating enrollm
Read more →ARVNArvinas to Present at Upcoming Conferences
NEW HAVEN, Conn., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming conferences: Society for Neurosc
Read more →ARVNArvinas Announces Winner of the 2022 Arvinas Early Career Researcher Award
NEW HAVEN, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation (TPD), announced Katherine Donovan, Ph.D. of the Dana-Farber Cancer Institute/Harvard Medic
Read more →ARVNArvinas Appoints Paul McInulty as Senior Vice President, Regulatory Affairs
NEW HAVEN, Conn., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Paul McInulty has joined the company as Senior Vice President, Regula
Read more →ARVNArvinas Gives Back to Local Greater New Haven Community
NEW HAVEN, Conn., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that nearly 200 employees participated in the Company’s inaugural “Arvina
Read more →ARVNArvinas to Present at Bank of America Securities Precision Oncology Conference
NEW HAVEN, Conn., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Bank of Americ
Read more →ARVNArvinas Appoints Lisa Sinclair as Senior Vice President, Corporate Operations
NEW HAVEN, Conn., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Lisa Sinclair has joined the company as Senior Vice President, Corpo
Read more →ARVNArvinas Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Arvinas Reports Second Quarter 2022 Financial Results and Provides Corporate Update NEW HAVEN, Conn. - August 4, 2022 - Arvinas, Inc. (Nasdaq ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financi
Read more →ARVN▼ -5.1%on this newsshared move
Arvinas Appoints John Northcott as Chief Commercial Officer
NEW HAVEN, Conn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Northcott has joined the company in a newly created position of
Read more →ARVNArvinas to Present at Goldman Sachs 43rd Annual Global Healthcare Conference
NEW HAVEN, Conn., June 02, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Goldman Sachs 4
Read more →ARVNArvinas Launches Global Early Career Researcher Award and Announces Call for Nominations
-- In honor of 20 years of targeted protein degradation, Arvinas announces $25,000 prize to recognize the efforts of an up-and-coming researcher in the field of targeted protein degradation – -- Global nomination deadline of August 1, 2022 -- NEW HAVEN, Conn., June 01, 2022 (GL
Read more →ARVN▼ -9.9%on this news· ran to -23% by day 3
Arvinas Reports First Quarter 2022 Financial Results and Provides Corporate Update
Arvinas Reports First Quarter 2022 Financial Results and Provides Corporate Update NEW HAVEN, Conn. - May 5, 2022 - Arvinas, Inc. (Nasdaq ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial r
Read more →ARVNArvinas to Present at Bank of America Securities 2022 Healthcare Conference
NEW HAVEN, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Bank of America
Read more →ARVNArvinas Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Arvinas Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update NEW HAVEN, Conn. February 28, 2022 Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today r
Read more →ARVNArvinas PROTAC Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer Bavdegalutamide treatment demonstrated robust activity in mo
Arvinas PROTAC Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer Bavdegalutamide treatment demonstrated robust activity in molecularly defined tumors (androgen receptor T878X/H875Y
Read more →ARVNArvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC Degrader Bavdegalutamide (ARV-110) to be Presented at 2022 ASCO GU Meeting Bavdegalutamide d
Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC Degrader Bavdegalutamide (ARV-110) to be Presented at 2022 ASCO GU Meeting Bavdegalutamide demonstrated a 46% PSA50 rate in patients with metastatic
Read more →ARVN▼ -6.8%on this news
Arvinas and Pfizer Announce PROTAC Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer ARV-471 continues to show a f
Arvinas and Pfizer Announce PROTAC Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer ARV-471 continues to show a favorable tolerability profile and robust ER degradation in
Read more →ARVNArvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium
NEW HAVEN, Conn. and NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced today that updated safety and efficacy data from the Phase 1 dose escalation trial of ARV-471, a novel oral estrogen receptor (ER)-targeting PROteol
Read more →ARVN▼ -5.4%on this news
Arvinas to Present at Stifel 2021 Virtual Healthcare Conference
NEW HAVEN, Conn., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Sean Cassidy, Chief Financial Officer, and Ian Taylor, Ph.D., Chief S
Read more →ARVNArvinas Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Arvinas Reports Third Quarter 2021 Financial Results and Provides Corporate Update NEW HAVEN, Conn. November 3, 2021 Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financia
Read more →ARVNArvinas to Participate in Upcoming Virtual Investor Conferences
NEW HAVEN, Conn., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming virtual investor conferences: C
Read more →ARVNArvinas Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Arvinas Reports Second Quarter 2021 Financial Results and Provides Corporate Update NEW HAVEN, Conn. August 5, 2021 Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial
Read more →ARVN▲ +9%on this news· ran to +23% by day 1
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC Protein Degrader ARV-471 Collaboration combines Arvinas investigational estrogen receptor-targeting breast cancer therapy with Pfizer s
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC Protein Collaboration combines Arvinas investigational estrogen receptor-targeting breast cancer therapy with Pfizer s deep experience in breast oncology therapeutics ARV-471 is currently in P
Read more →ARVNArvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven
NEW HAVEN, Conn., June 07, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today joined state and local officials, fellow tenants, and community partners, in a groun
Read more →ARVNArvinas to Present at the 42nd Annual Goldman Sachs Global Healthcare Conference
NEW HAVEN, Conn., June 03, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ron Peck, M.D., Chief Medical Officer, and Sean Cassidy, Chief Financ
Read more →ARVNArvinas to Present at the UBS Global Healthcare Virtual Conference
NEW HAVEN, Conn., May 20, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer and Ian Tay
Read more →ARVNArvinas Reports First Quarter 2021 Financial Results and Provides Corporate Update
Arvinas Reports First Quarter 2021 Financial Results and Provides Corporate Update NEW HAVEN, Conn., May 4, 2021 Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today reported financia
Read more →ARVNArvinas Signs Lease for New Space Within Downtown Crossing Development in New Haven
NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will be leasing three of the 10 floors at 101 College Street in New
Read more →ARVNArvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021
NEW HAVEN, Conn., April 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced two upcoming presentations at the American Association for Cancer Researc
Read more →ARVNArvinas Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Arvinas Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update NEW HAVEN, Conn., March 1, 2021 Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today
Read more →ARVNArvinas to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day
NEW HAVEN, Conn., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer and Ian Ta
Read more →ARVNArvinas, Inc. Announces Exercise of Underwriters’ Option to Purchase Additional Shares
NEW HAVEN, Conn., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC® Discovery Engine, today announced that the underwriters of its previously
Read more →ARVNArvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock
Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock NEW HAVEN, Conn., December 15, 2020 Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC Discover
Read more →ARVNArvinas, Inc. Announces Proposed Offering of Common Stock
NEW HAVEN, Conn., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC® Discovery Engine, today announced that it is commencing an underwritten p
Read more →ARVNArvinas Releases Interim Clinical Data Further Demonstrating the Powerful Potential of PROTAC Protein Degraders ARV-471 and ARV-110 ARV-471 demonstrates evidence of anti-tumor activity, and potential for best-in-class sa
Arvinas Releases Interim Clinical Data Further Demonstrating the Powerful Potential of PROTAC Protein Degraders ARV-471 and ARV-110 ARV-471 demonstrates evidence of anti-tumor activity, and potential for best-in-class safety, and estrogen receptor (ER) degradation profile and ro
Read more →ARVNArvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC Protein Degrader Development Programs
– Event to be webcast live on Monday, December 14, 2020 at 8:00 a.m. ET – NEW HAVEN, Conn., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced
Read more →ARVNArvinas Reports Third Quarter 2020 Financial Results and Provides Corporate Update First patient dosed in Phase 2 dose expansion cohort of ARV-110 trial Dose escalation for Phase 1/2 clinical trials of ARV-110 and ARV-47
Arvinas Reports Third Quarter 2020 Financial Results and Provides Corporate Update First patient dosed in Phase 2 dose expansion cohort of ARV-110 trial Dose escalation for Phase 1/2 clinical trials of ARV-110 and ARV-471 continues; program updates planned for December 2020 P
Read more →ARVNMost B cell lymphomas are dependent on constitutive or deregulated expression of BCL6, a transcriptional repressor of: Cell cycle checkpoints Terminal differentiation Apoptosis DNA damage response PROTAC degradation woul
1 Today: Introducing five targets for which PROTAC protein degraders have high potential to differentiate from other drug modalities KRAS Oncogenic cell growth regulator BCL6 Transcription factor implicated in B cell lymphomas Myc Oncogenic transcription factor driving tumor cel
Read more →ARVNArvinas Announces Pipeline Programs Targeting Validated and Classically “Undruggable” Disease-Causing Proteins
NEW HAVEN, Conn., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced platform updates and disclosed five additional programs from its preclinic
Read more →ARVNArvinas to Present at the 3rd Annual Targeted Protein Degradation Summit
NEW HAVEN, Conn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer, will pres
Read more →ARVNArvinas to Present at the Citi 15th Annual BioPharma Virtual Conference
NEW HAVEN, Conn., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a f
Read more →ARVNArvinas to Present at the 2020 Wedbush PacGrow Virtual Healthcare Conference
NEW HAVEN, Conn., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ron Peck, M.D., Chief Medical Officer, will participate in a fireside
Read more →ARVNArvinas Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Arvinas Reports Second Quarter 2020 Financial Results and Provides Corporate Update NEW HAVEN, Conn., August 4, 2020 Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today reported fina
Read more →ARVNArvinas Appoints Wendy Dixon, Ph.D., to its Board of Directors
NEW HAVEN, Conn., June 29, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Wendy Dixon, Ph.D., has joined its Board of Directors. Dr. Dixon is a
Read more →ARVNArvinas to Present Virtually at the BMO 2020 Prescriptions for Success Healthcare Conference
NEW HAVEN, Conn., June 17, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fi
Read more →ARVNArvinas Appoints Linda Bain to its Board of Directors
NEW HAVEN, Conn., June 11, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Linda Bain has joined its Board of Directors. Ms. Bain, who is curren
Read more →ARVNArvinas to Present Virtually at the Goldman Sachs 41st Annual Global Healthcare Conference
NEW HAVEN, Conn., June 05, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ron Peck, M.D., Chief Medical Officer, will participate in a fireside
Read more →ARVNArvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC Protein Degrader ARV-110 in Patients with Metastatic Castration-Resistant Prostate Cancer - Clear efficacy signal with two ongoing confirmed PSA
Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC Protein Degrader with Metastatic Castration-Resistant Prostate Cancer - Clear efficacy signal with two ongoing confirmed PSA responses, including one associated with a confirmed RECIST response - - Da
Read more →ARVNArvinas to Hold Virtual 2020 Annual Meeting of Stockholders
NEW HAVEN, Conn., May 20, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that its 2020 Annual Meeting of Stockholders, to be held on Wednesday, June
Read more →ARVNArvinas Announces Updated Phase 1 Data Demonstrating Clinical Activity of PROTAC Protein Degrader ARV-110 in Patients with Refractory Prostate Cancer
- Describes the first evidence of clinical benefit for PROTAC® protein degraders, a novel therapeutic modality - - Data to be presented during the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting - NEW HAVEN, Conn., May 13, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc.
Read more →ARVNArvinas Reports First Quarter 2020 Financial Results and Provides a Corporate Update
Arvinas Reports First Quarter 2020 Financial Results and Provides a Corporate Update NEW HAVEN, Conn. April 28, 2020 Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financia
Read more →ARVNArvinas Provides Update on Business Continuity Related to the Impact of the COVID-19 Pandemic
NEW HAVEN, Conn., April 13, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today provided an update regarding the impact of the COVID-19 pandemic on its overall bus
Read more →ARVNArvinas to Present at the American Society of Clinical Oncology Annual Meeting
NEW HAVEN, Conn., March 31, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the acceptance of an abstract for presentation at the American Society of
Read more →ARVNArvinas Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Arvinas Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update NEW HAVEN, Conn. March 16, 2020 Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today repo
Read more →ARVNArvinas to Present at the 31st Annual Piper Jaffray Healthcare Conference
NEW HAVEN, Conn., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at t
Read more →ARVNArvinas Appoints Laurie Smaldone Alsup, M.D., to Board of Directors
NEW HAVEN, Conn., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced today that Laurie Smaldone Alsup, M.D., has joined its board of directors. Dr. Smaldone Alsup,
Read more →ARVNArvinas, Inc. Announces Pricing of Public Offering of Common Stock
Arvinas, Inc. Announces Pricing of Public Offering of Common Stock NEW HAVEN, Conn., November 6, 2019 Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the pricing of an underwritten public
Read more →ARVNArvinas Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Arvinas Reports Third Quarter 2019 Financial Results and Provides Corporate Update NEW HAVEN, Conn. November 4, 2019 Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today reported fina
Read more →ARVNArvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC Targeted Protein Degraders -Data from initial cohorts suggest that Arvinas PROTAC platform has the potential to crea
Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC Targeted Protein Degraders -Data from initial cohorts suggest that Arvinas PROTAC platform has the potential to create safe and well-tolerated orally bioavailable drugs for
Read more →ARVNArvinas to Present Initial Data from Ongoing Clinical Trials and a Pipeline Update at the 2nd Targeted Protein Degradation Summit
Platform Presentation to Include Initial Safety, Tolerability, and Pharmacokinetic Data from Ongoing Phase 1 Trials Neuroscience Presentation to Include Data from Preclinical Tau and Alpha-Synuclein Programs NEW HAVEN, Conn., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc., (Nas
Read more →ARVNArvinas Strengthens Scientific Advisory Board with Leaders in Oncology and Neurological Disorders
NEW HAVEN, Conn., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced that six new thought leaders will join the company’s scientific advisory board (SAB). The new m
Read more →ARVNArvinas Announces the Initiation of Patient Dosing in a First-in-Human Phase 1 Study of ARV-471, an Estrogen Receptor-Targeting PROTAC Protein Degrader
NEW HAVEN, Conn., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the initiation of patient dosing in its second clinical program. The Phase 1 clinical tri
Read more →ARVNArvinas To Present at the Wedbush PacGrow Healthcare Conference
NEW HAVEN, Conn. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the company is scheduled to present at the 2019 Wedbush PacGrow Healthcare Conferenc
Read more →ARVNArvinas Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Arvinas Reports Second Quarter 2019 Financial Results and Provides Corporate Update NEW HAVEN, Conn. August 5, 2019 Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for th
Read more →ARVNArvinas Appoints Ronald Peck, M.D. as Chief Medical Officer
NEW HAVEN, Conn., July 29, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced today the appointment of Ronald Peck, M.D. to the newly created position of Chief Medical Offic
Read more →ARVNArvinas Strengthens Board of Directors with Addition of Leslie Norwalk
NEW HAVEN, Conn., July 25, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced today that Leslie Norwalk, Esq., will join its Board of Directors. Ms. Norwalk provides strateg
Read more →ARVNArvinas to Present Preclinical Tau-Directed PROTAC Protein Degrader Data at Alzheimer's Association International Conference
NEW HAVEN, Conn., July 18, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced it will present preclinical data from its tau-targeted PROTAC® protein degrader program at the
Read more →ARVNArvinas Receives Authorization to Proceed for ARV-471, a PROTAC Protein Degrader to Treat Patients with Locally Advanced or Metastatic ER+ / HER2- Breast Cancer
- Initiation of Phase 1 Trial expected in the third quarter of 2019 - ARV-471 will be Arvinas’ second targeted PROTAC® protein degrader to enter the clinic NEW HAVEN, Conn., June 25, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new c
Read more →ARVNArvinas to Present at the BMO Prescriptions for Success Healthcare Conference
NEW HAVEN, Conn., June 20, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the BMO Pr
Read more →ARVNArvinas to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
NEW HAVEN, Conn., June 06, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Goldma
Read more →ARVNArvinas Receives Fast Track Designation for its Targeted Protein Degrader ARV-110 as a Treatment for Men with Metastatic Castration-Resistant Prostate Cancer
NEW HAVEN, Conn., May 29, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies that degrades disease-causing proteins, today announced that its lead PROTAC® protein degrader, ARV-110, has been granted Fast Track desi
Read more →ARVNArvinas Reports First Quarter Financial Results and Provides Corporate Update Initiated Patient Dosing in the First Phase 1 Clinical Trial with a Targeted PROTAC Protein Degrader, ARV-110
Arvinas Reports First Quarter Financial Results and Provides Corporate Update Initiated Patient Dosing in the First Phase 1 Clinical Trial with a Targeted PROTAC Protein Degrader, ARV-110 NEW HAVEN, Conn. May 8, 2019 Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company cr
Read more →ARVNArvinas Strengthens Management Team with Internal Appointments of Andy Crew, Ph.D. as Chief Technology Officer and Ian Taylor, Ph.D. as Chief Scientific Officer
NEW HAVEN, Conn., April 02, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies that degrades disease-causing proteins, announced that two members of the senior leadership team were appointed to expanded roles at th
Read more →ARVNArvinas Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update Recently Announced the Initiation of Patient Dosing in the First Phase 1 Clinical Trial with a Targeted PROTAC Protein Deg
Arvinas Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update Recently Announced the Initiation of Patient Dosing in the First Phase 1 Clinical Trial with a Targeted PROTAC Protein Degrader ARV-110 NEW HAVEN, Conn. March 26, 2019 Arvinas, In
Read more →ARVNArvinas Announces Initiation of Patient Dosing in the First Phase 1 Clinical Trial of PROTAC™ Protein Degrader, ARV-110
NEW HAVEN, Conn., March 25, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies that degrade disease-causing proteins, today announced the initiation of patient dosing in its Phase 1 clinical trial of ARV-110, the c
Read more →ARVNArvinas Announces Poster Presentation at ASCO 2019 Genitourinary Cancers Symposium
NEW HAVEN, Conn., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced that it will present a poster at the 2019 American Society of Clinical Oncology Genitourinary Cance
Read more →ARVNArvinas Receives Authorization to Proceed for its IND Application for PROTAC™ Therapy to Treat Patients with Metastatic Castration-Resistant Prostate Cancer
NEW HAVEN, Conn., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigationa
Read more →ARVNArvinas Presents Preclinical Data on Protein Degrader, ARV-471, at the 2018 San Antonio Breast Cancer Symposium (SABCS)
NEW HAVEN, Conn., Dec. 07, 2018 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today presented positive preclinical data on the company's lead clinical candidate, ARV-471, for advanced
Read more →ARVNArvinas To Present at the 30th Annual Piper Jaffray Healthcare Conference
NEW HAVEN, Conn., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced that John G. Houston, Ph.D., President and Chief Executive Officer, will participate in a fireside
Read more →ARVNArvinas to Present at Two Protein Degradation Conferences
NEW HAVEN, Conn., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced it will be presenting at two upcoming conferences focused on protein degradation. The first is the
Read more →ARVNArvinas Announces Pricing of Initial Public Offering
NEW HAVEN, Conn., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therap
Read more →Competitive Position
How ARVN ranks across every disease it competes inCompetitive Position is a premium feature
See how ARVN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial